akorn.comAkorn Pharmaceuticals

Akorn.com About Us (current) About Akorn Akorn Leadership Akorn Timeline Operating Locations Annual Reports -- Policies Suppliers -- Our Businesses Our Businesses Specialty Pharmaceuticals Brand Rx Akorn Consumer Health Akorn Animal Health Akorn Eye Care Products All Products Return Goods Policy News News Events Media Contact Careers Career Opportunities Who Are We? Why Akorn? Training & Development Life at Akorn Akorn Benefits A specialty pharmaceutical company Make MEDICINE. We Make MEMORIES. -- Who We Are At Akorn, we develop, manufacture and market specialty pharmaceuticals, including prescription, consumer health and animal health products. As an industry leader in branded and generic products in alternate dosage forms such as ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays, we focus each day on our mission to improve lives, through the quality, availability and affordability of our products. With deep roots in both branded and generic ophthalmics, since 1971, Akorn Eye Care has been supporting the eye care community. We are passionately at work in every aspect of eye health - whether anterior or posterior, diagnostic or therapeutic. Our Akorn Consumer Health division markets a portfolio of over-the-counter (OTC) brands and private-label OTC products. Our flagship OTC brand is TheraTears® Therapy for Your Eyes®, which is a family of therapeutic eye care products including dry eye therapy lubricating eye drops, antimicrobial eyelid cleanser and eye nutrition supplements. Our Akorn Animal Health division manufactures and distributes a full line of diagnostic, therapeutic and OTC ophthalmics, as well as specialty niche injectable drugs for the veterinary marketplace. Our Mission We are a vibrant pharmaceutical company dedicated to improving patients’ lives through the quality, availability and affordability of our products. RECENT NEWS 02/26/21 Akorn Announces Review of Strategic Alternatives for the Akorn Consumer Health Business More >> 02/11/21 Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Gel, 0.5% More >> 10/28/20 Akorn Announces Its New Board of Directors More >> 10/01/20 Akorn Successfully Completes Sale to Lenders and Exits Chapter 11 Protection More >> 08/07/20 Akorn Provides Second Quarter 2020 Results More 06/22/20 Akorn Animal Health Announces Launch of Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment More 05/20/20 Akorn to Use Voluntary Chapter 11 Process to Position Business for Long-Term Success More 05/11/20 Akorn Provides First Quarter 2020 Results More -- 03/26/20 Akorn COVID-19 Statement More >> Jan 1, 2019 your content Jan 1, 2019 your content Jan 1, 2019 your content -- NASDAQ: AKRX $ % Apr. 20, 2021 12:33 PM CDT Minimum 15 Minutes Delayed -- RECENT NEWS ... Read More ... Read More ... Read More Jan 1, 2019 your content Jan 1, 2019 your content Jan 1, 2019 your content -- Featured Products Gentak® (gentamicin sulfate ophthalmic ointment, USP) Mycophenolate Mofetil Injection, USP Lidocaine Hydrochloride Jelly, USP Loteprednol Etabonate Ophthalmic Suspension BAL in Oil™ (dimercaprol injection, USP) © Copyright 2021 Akorn, Incorporated All Rights Reserved 1925 W. Field Court, Suite 300, Lake Forest, Illinois 60045 | 800.932.5676 Home Contact Legal & Privacy Return Goods Policy Site Map...